PMID- 30614072
OWN - NLM
STAT- Publisher
LR  - 20190123
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 6
TI  - Ethnicity and Type 2 diabetes in the UK.
LID - 10.1111/dme.13895 [doi]
AB  - Type 2 diabetes is a major UK public health priority. Among minority ethnic
      communities, the prevalence is alarmingly high, approximately three to five times
      higher than in the white British population. Particularly striking is the earlier
      onset of Type 2 diabetes, which occurs some 10-12 years younger, with a
      significant proportion of cases being diagnosed before the age of 40 years. This 
      review focuses on the UK context and Type 2 diabetes in adult populations,
      exploring the available evidence regarding the complex interplay of biological,
      lifestyle, social, clinical and healthcare system factors that are known to drive
      these disparities.
CI  - (c) 2019 Diabetes UK.
FAU - Goff, L M
AU  - Goff LM
AUID- ORCID: https://orcid.org/0000-0001-9633-8759
AD  - Diabetes Research Group, Departments of Diabetes and Nutritional Sciences, King's
      College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190106
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/08 06:00
MHDA- 2019/01/08 06:00
CRDT- 2019/01/08 06:00
PHST- 2019/01/04 00:00 [accepted]
PHST- 2019/01/08 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2019/01/08 06:00 [entrez]
AID - 10.1111/dme.13895 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 6. doi: 10.1111/dme.13895.

PMID- 30614070
OWN - NLM
STAT- Publisher
LR  - 20190125
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 6
TI  - Time trends in diabetes mellitus in Jordan between 1994 and 2017.
LID - 10.1111/dme.13894 [doi]
AB  - AIM: The prevalence of diabetes has been increasing over the past few decades.
      The objective of this study is to assess the time trends in diabetes between 1994
      and 2017 in Jordan. METHODS: Surveys were conducted in 1994, 2004, 2009 and 2017 
      by the same investigators using generally similar methods. Fasting blood glucose 
      was measured in all surveys. Variables were obtained using structured
      questionnaires designed specifically for the surveys. Crude and age-specific
      diabetes prevalence rates were derived for each sex, together with overall, crude
      and age-standardized prevalence rates. RESULTS: The prevalence of diabetes in men
      aged >/= 25 years increased from 14.2% in 1994 to 18.3% in 2004, 26.8% in 2009
      and 32.4% in 2017. The corresponding prevalence rates in women were 12.3%, 16.9%,
      18.8%, and 18.1%, respectively. The overall age-standardized prevalence rate
      increased from 13.0% in 1994 to 17.1% in 2004, 22.2% in 2009 and 23.7% in 2017.
      Known diabetes in the 2017 survey accounted for 82.6% of people with diabetes. A 
      HbA1c of < 59 mmol/mol (7.5%) was observed in 41.4% of participants with known
      diabetes. CONCLUSION: The results showed a high prevalence of diabetes in Jordan 
      among people aged >/= 25 years. Prevalence increased from 1994 to 2009, but
      slowed thereafter. The increase was greater in men than in women. Previously
      diagnosed diabetes accounted for a high percentage of people with diabetes in all
      surveys and was highest in 2017 survey, suggesting that the national strategy
      against diabetes has brought some benefits. Efforts should be made to improve
      glycaemic control in people with diabetes.
CI  - (c) 2019 Diabetes UK.
FAU - Ajlouni, K
AU  - Ajlouni K
AUID- ORCID: https://orcid.org/0000-0001-5569-6306
AD  - National Centre (Institute) for Diabetes, Endocrinology and Genetics (NCDEG),
      University of Jordan, Amman.
FAU - Batieha, A
AU  - Batieha A
AD  - Department of Public Health and Community Medicine, Jordan University of Science 
      and Technology (JUST), Irbid.
FAU - Jaddou, H
AU  - Jaddou H
AD  - Department of Public Health and Community Medicine, Jordan University of Science 
      and Technology (JUST), Irbid.
FAU - Khader, Y
AU  - Khader Y
AD  - Department of Public Health and Community Medicine, Jordan University of Science 
      and Technology (JUST), Irbid.
FAU - Abdo, N
AU  - Abdo N
AD  - Department of Public Health and Community Medicine, Jordan University of Science 
      and Technology (JUST), Irbid.
FAU - El-Khateeb, M
AU  - El-Khateeb M
AD  - National Centre (Institute) for Diabetes, Endocrinology and Genetics (NCDEG),
      University of Jordan, Amman, Jordan.
FAU - Hyassat, D
AU  - Hyassat D
AD  - National Centre (Institute) for Diabetes, Endocrinology and Genetics (NCDEG),
      University of Jordan, Amman, Jordan.
FAU - Al-Louzi, D
AU  - Al-Louzi D
AD  - Jordan Ministry of Health, Amman, Jordan.
LA  - eng
GR  - Scientific Research Support Fund/The Ministry of Higher Education
PT  - Journal Article
DEP - 20190106
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/08 06:00
MHDA- 2019/01/08 06:00
CRDT- 2019/01/08 06:00
PHST- 2019/01/04 00:00 [accepted]
PHST- 2019/01/08 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2019/01/08 06:00 [entrez]
AID - 10.1111/dme.13894 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 6. doi: 10.1111/dme.13894.

PMID- 30614066
OWN - NLM
STAT- Publisher
LR  - 20190128
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 6
TI  - Management of people with Type 2 diabetes shared between a specialized outpatient
      clinic and primary health care is noninferior to management in a specialized
      outpatient clinic: a randomized, noninferiority trial.
LID - 10.1111/dme.13896 [doi]
AB  - AIM: To evaluate whether management of people with Type 2 diabetes shared between
      a specialized outpatient clinic and primary health care has noninferior HbA1c
      outcomes compared with mono-sectorial management in a specialized outpatient
      clinic. METHODS: A randomized controlled, noninferiority study. People with
      moderate hyperglycaemia, hypertension and/or incipient complications were
      eligible for the study. All participants had annual comprehensive check-ups at
      the outpatient clinic. Quarterly check-ups were conducted by general
      practitioners (GPs) for the shared care group and by endocrinologists at the
      outpatient clinic for the control group. The primary outcome was the mean
      difference in HbA1c from baseline to 12 months of follow-up. The noninferiority
      margin for HbA1c was 4.4 mmol/mol. RESULTS: A total of 140 people were randomized
      [age 65.0 +/- 0.9 years, HbA1c 52 +/- 0.8 mmol/mol (6.9 +/- 0.1%), systolic BP
      135.6 +/- 1.1 mmHg; all mean +/- sem]. Peripheral neuropathy was present in 68%
      of participants and microalbuminuria in 19%; 15% had history of a previous major 
      cardiovascular event. Among study completers (n = 133), HbA1c increased by 2.3
      mmol/mol (0.2%) in the shared care group and by 1.0 mmol/mol (0.1%) in the
      control group, with a between-group difference of 1.3 mmol/mol [90% confidence
      interval (CI) -1.3, 3.9] (0.1%, 90% CI -0.1, 0.4). Noninferiority was confirmed
      in both per protocol and intention to treat analyses. CONCLUSION: We found that
      our shared care programme was noninferior to specialized outpatient management in
      maintaining glycaemic control in this group of people with Type 2 diabetes.
      Shared care should be considered for the future diabetes management of Type 2
      diabetes.
CI  - (c) 2019 Diabetes UK.
FAU - Munch, L
AU  - Munch L
AD  - Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, University of
      Copenhagen, Gentofte.
AD  - Institute of Nursing, University College Copenhagen, Copenhagen, Denmark.
FAU - Bennich, B B
AU  - Bennich BB
AD  - Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, University of
      Copenhagen, Gentofte.
AD  - Institute of Nursing, University College Copenhagen, Copenhagen, Denmark.
FAU - Overgaard, D
AU  - Overgaard D
AD  - Institute of Nursing, University College Copenhagen, Copenhagen, Denmark.
FAU - Konradsen, H
AU  - Konradsen H
AD  - Department of Neurobiology, Care Sciences and Society, Karolinska Institute,
      Huddinge, Sweden.
FAU - Middelfart, H
AU  - Middelfart H
AD  - Rudersdalklinikken, Holte.
FAU - Kaarsberg, N
AU  - Kaarsberg N
AD  - Vangede Laegehus, Gentofte.
FAU - Knop, F K
AU  - Knop FK
AD  - Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, University of
      Copenhagen, Gentofte.
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, University of
      Copenhagen, Copenhagen.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen.
FAU - Vilsboll, T
AU  - Vilsboll T
AD  - Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, University of
      Copenhagen, Gentofte.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen.
FAU - Roder, M E
AU  - Roder ME
AUID- ORCID: https://orcid.org/0000-0002-5671-5385
AD  - Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, University of
      Copenhagen, Gentofte.
AD  - Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
LA  - eng
GR  - Jascha Foundation, Lilly
GR  - Herbert Hansen's Foundation
GR  - Capital Region of Denmark
PT  - Journal Article
DEP - 20190106
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/08 06:00
MHDA- 2019/01/08 06:00
CRDT- 2019/01/08 06:00
PHST- 2019/01/04 00:00 [accepted]
PHST- 2019/01/08 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2019/01/08 06:00 [entrez]
AID - 10.1111/dme.13896 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 6. doi: 10.1111/dme.13896.

PMID- 30614052
OWN - NLM
STAT- Publisher
LR  - 20190123
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 6
TI  - The cost of treating diabetic ketoacidosis in an adolescent population in the UK:
      a national survey of hospital resource use.
LID - 10.1111/dme.13893 [doi]
AB  - AIMS: Adolescents with Type 1 diabetes commonly experience episodes of
      ketoacidosis. In 2014, we conducted a nationwide survey on the management of
      diabetic ketoacidosis in young people. The survey reported how individual
      adolescents with diabetes were managed. However, the costs of treating diabetic
      ketoacidosis were not reported. METHODS: Using this mixed population sample of
      adolescents, we took a 'bottom-up' approach to cost analysis aiming to determine 
      the total expense associated with treating diabetic ketoacidosis. The data were
      derived using the information from the national UK survey of 71 individuals,
      collected via questionnaires sent to specialist paediatric diabetes services in
      England and Wales. RESULTS: Several assumptions had to be made when analysing the
      data because the initial survey collection tool was not designed with a health
      economic model in mind. The mean time to resolution of diabetic ketoacidosis was 
      15.0 h [95% confidence interval (CI) 13.2, 16.8] and the mean total length of
      stay was 2.4 days (95% CI 1.9, 3.0). Based on data for individuals and using the 
      British Society of Paediatric Endocrinology and Diabetes (BSPED) guidelines, the 
      cost analysis shows that for this cohort, the average cost for an episode of
      diabetic ketoacidosis was pound1387 (95% CI 1120, 1653). Regression analysis
      showed a significant cost saving of pound762 (95% CI 140, 1574; P = 0.04) among
      those treated using BSPED guidelines. CONCLUSION: We have used a bottom-up
      approach to calculate the costs of an episode of diabetic ketoacidosis in
      adolescents. These data suggest that following treatment guidelines can
      significantly lower the costs for managing episodes of diabetic ketoacidosis.
CI  - (c) 2019 Diabetes UK.
FAU - Dhatariya, K K
AU  - Dhatariya KK
AUID- ORCID: https://orcid.org/0000-0003-3619-9579
AD  - Elsie Bertram Diabetes Centre, Norfolk and Norwich University Hospitals NHS
      Foundation Trust, Norwich, UK.
AD  - Norwich Medical School, University of East Anglia, Norwich, UK.
FAU - Parsekar, K
AU  - Parsekar K
AD  - Health Economics Consulting, Norwich Medical School, University of East Anglia,
      Norwich, UK.
FAU - Skedgel, C
AU  - Skedgel C
AD  - Health Economics Consulting, Norwich Medical School, University of East Anglia,
      Norwich, UK.
FAU - Datta, V
AU  - Datta V
AD  - Diabetes Department, Jenny Lind Children's Hospital, Norfolk and Norwich
      University Hospitals NHS Foundation Trust, Norwich, UK.
FAU - Hill, P
AU  - Hill P
AD  - Diabetes Department, Jenny Lind Children's Hospital, Norfolk and Norwich
      University Hospitals NHS Foundation Trust, Norwich, UK.
FAU - Fordham, R
AU  - Fordham R
AD  - Health Economics Consulting, Norwich Medical School, University of East Anglia,
      Norwich, UK.
LA  - eng
PT  - Journal Article
DEP - 20190106
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/08 06:00
MHDA- 2019/01/08 06:00
CRDT- 2019/01/08 06:00
PHST- 2019/01/04 00:00 [accepted]
PHST- 2019/01/08 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2019/01/08 06:00 [entrez]
AID - 10.1111/dme.13893 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 6. doi: 10.1111/dme.13893.

PMID- 30626609
OWN - NLM
STAT- In-Data-Review
LR  - 20190221
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 3
DP  - 2019 Mar
TI  - The Role of Prostaglandins in Disrupted Gastric Motor Activity Associated With
      Type 2 Diabetes.
PG  - 637-647
LID - 10.2337/db18-1064 [doi]
AB  - Patients with diabetes often develop gastrointestinal motor problems, including
      gastroparesis. Previous studies have suggested this gastric motor disorder was a 
      consequence of an enteric neuropathy. Disruptions in interstitial cells of Cajal 
      (ICC) have also been reported. A thorough examination of functional changes in
      gastric motor activity during diabetes has not yet been performed. We
      comprehensively examined the gastric antrums of Lep(ob) mice using functional,
      morphological, and molecular techniques to determine the pathophysiological
      consequences in this type 2 diabetic animal model. Video analysis and isometric
      force measurements revealed higher frequency and less robust antral contractions 
      in Lep(ob) mice compared with controls. Electrical pacemaker activity was reduced
      in amplitude and increased in frequency. Populations of enteric neurons, ICC, and
      platelet-derived growth factor receptor alpha(+) cells were unchanged. Analysis
      of components of the prostaglandin pathway revealed upregulation of multiple
      enzymes and receptors. Prostaglandin-endoperoxide synthase-2 inhibition increased
      slow wave amplitudes and reduced frequency of diabetic antrums. In conclusion,
      gastric pacemaker and contractile activity is disordered in type 2 diabetic mice,
      and this appears to be a consequence of excessive prostaglandin signaling.
      Inhibition of prostaglandin synthesis may provide a novel treatment for diabetic 
      gastric motility disorders.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Blair, Peter J
AU  - Blair PJ
AD  - Department of Physiology and Cell Biology, University of Nevada, Reno School of
      Medicine, Reno, NV.
FAU - Hwang, Sung Jin
AU  - Hwang SJ
AD  - Department of Physiology and Cell Biology, University of Nevada, Reno School of
      Medicine, Reno, NV.
FAU - Shonnard, Matthew C
AU  - Shonnard MC
AD  - Department of Physiology and Cell Biology, University of Nevada, Reno School of
      Medicine, Reno, NV.
FAU - Peri, Lauren E
AU  - Peri LE
AD  - Department of Physiology and Cell Biology, University of Nevada, Reno School of
      Medicine, Reno, NV.
FAU - Bayguinov, Yulia
AU  - Bayguinov Y
AD  - Department of Physiology and Cell Biology, University of Nevada, Reno School of
      Medicine, Reno, NV.
FAU - Sanders, Kenton M
AU  - Sanders KM
AD  - Department of Physiology and Cell Biology, University of Nevada, Reno School of
      Medicine, Reno, NV.
FAU - Ward, Sean M
AU  - Ward SM
AUID- ORCID: http://orcid.org/0000-0003-0217-1535
AD  - Department of Physiology and Cell Biology, University of Nevada, Reno School of
      Medicine, Reno, NV smward@med.unr.edu.
LA  - eng
PT  - Journal Article
DEP - 20190109
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/01/11 06:00
MHDA- 2019/01/11 06:00
CRDT- 2019/01/11 06:00
PHST- 2018/10/08 00:00 [received]
PHST- 2018/11/26 00:00 [accepted]
PHST- 2019/01/11 06:00 [pubmed]
PHST- 2019/01/11 06:00 [medline]
PHST- 2019/01/11 06:00 [entrez]
AID - db18-1064 [pii]
AID - 10.2337/db18-1064 [doi]
PST - ppublish
SO  - Diabetes. 2019 Mar;68(3):637-647. doi: 10.2337/db18-1064. Epub 2019 Jan 9.

PMID- 30626607
OWN - NLM
STAT- Publisher
LR  - 20190110
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2019 Jan 9
TI  - Epitope Stealing as Mechanism of Dominant Protection by HLA-DQ6 in Type 1
      Diabetes.
LID - db180501 [pii]
LID - 10.2337/db18-0501 [doi]
FAU - van Lummel, Menno
AU  - van Lummel M
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, the Netherlands, The Netherlands.
FAU - Buis, David T P
AU  - Buis DTP
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, the Netherlands, The Netherlands.
FAU - Ringeling, Cherish
AU  - Ringeling C
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, the Netherlands, The Netherlands.
FAU - de Ru, Arnoud H
AU  - de Ru AH
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, the Netherlands, The Netherlands.
FAU - Pool, Jos
AU  - Pool J
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, the Netherlands, The Netherlands.
FAU - Papadopoulos, George K
AU  - Papadopoulos GK
AD  - Laboratory of Biochemistry and Biophysics, Faculty of Agricultural Technology,
      Epirus Institute of Technology, Arta, Greece.
FAU - van Veelen, Peter A
AU  - van Veelen PA
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, the Netherlands, The Netherlands.
FAU - Reijonen, Helena
AU  - Reijonen H
AD  - Department of Diabetes Immunology, Diabetes & Metabolism Research Institute at
      the Beckman Research Institute, City of Hope, Duarte, USA.
FAU - Drijfhout, Jan W
AU  - Drijfhout JW
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, the Netherlands, The Netherlands.
FAU - Roep, Bart O
AU  - Roep BO
AD  - Department of Immunohematology and Blood Transfusion, Leiden University Medical
      Center, the Netherlands, The Netherlands boroep@lumc.nl.
AD  - Department of Diabetes Immunology, Diabetes & Metabolism Research Institute at
      the Beckman Research Institute, City of Hope, Duarte, USA.
LA  - eng
PT  - Journal Article
DEP - 20190109
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/01/11 06:00
MHDA- 2019/01/11 06:00
CRDT- 2019/01/11 06:00
PHST- 2018/05/03 00:00 [received]
PHST- 2018/12/28 00:00 [accepted]
PHST- 2019/01/11 06:00 [entrez]
PHST- 2019/01/11 06:00 [pubmed]
PHST- 2019/01/11 06:00 [medline]
AID - db18-0501 [pii]
AID - 10.2337/db18-0501 [doi]
PST - aheadofprint
SO  - Diabetes. 2019 Jan 9. pii: db18-0501. doi: 10.2337/db18-0501.

PMID- 30617218
OWN - NLM
STAT- Publisher
LR  - 20190108
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2019 Jan 7
TI  - Structural and Functional Abnormalities of the Primary Somatosensory Cortex in
      Diabetic Peripheral Neuropathy: A Multimodal MRI Study.
LID - db180509 [pii]
LID - 10.2337/db18-0509 [doi]
AB  - Diabetic distal symmetrical peripheral polyneuropathy (DSP) results in decreased 
      somatosensory cortical gray matter volume, indicating that the disease process
      may produce morphological changes in the brains of those affected. However, no
      study has examined whether changes in brain volume alters the functional
      organisation of the somatosensory cortex and how this relates to the different
      painful DSP clinical phenotypes. In this case-controlled, multimodal magnetic
      resonance brain imaging study of 44 carefully phenotyped subjects, we found
      significant anatomical and functional changes in the somatosensory cortex.
      Painful DSP insensate subjects have the lowest somatosensory cortical thickness
      with expansion of the area representing pain in the lower limb to include face
      and lip regions. Furthermore, there was a significant relationship between
      anatomical and functional changes within the somatosensory cortex and severity of
      the peripheral neuropathy. These data suggest a dynamic plasticity of the brain
      in DSP, driven by the neuropathic process. It demonstrates, for the first time, a
      pathophysiological relationship between a clinical painful DSP phenotype and
      alterations in the somatosensory cortex.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Selvarajah, Dinesh
AU  - Selvarajah D
AD  - Department of Human Metabolism, University of Sheffield, Sheffield, UK
      d.selvarajah@sheffield.ac.uk.
FAU - Wilkinson, Iain D
AU  - Wilkinson ID
AD  - Academic Department of Magnetic Resonance Imaging, University of Sheffield,
      Sheffield, UK.
FAU - Fang, Fang
AU  - Fang F
AD  - Department of Neurophysiology, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
FAU - Sankar, Adithya
AU  - Sankar A
AD  - Academic Department of Magnetic Resonance Imaging, University of Sheffield,
      Sheffield, UK.
FAU - Davies, Jennifer
AU  - Davies J
AD  - Academic Department of Magnetic Resonance Imaging, University of Sheffield,
      Sheffield, UK.
FAU - Boland, Elaine
AU  - Boland E
AD  - Academic Department of Magnetic Resonance Imaging, University of Sheffield,
      Sheffield, UK.
FAU - Harding BMedSci, Joseph
AU  - Harding BMedSci J
AD  - Department of Human Metabolism, University of Sheffield, Sheffield, UK.
FAU - Rao, Ganesh
AU  - Rao G
AD  - Department of Neurophysiology, Sheffield Teaching Hospitals NHS Foundation Trust,
      Sheffield, UK.
FAU - Gandhi, Rajiv
AU  - Gandhi R
AD  - Diabetes Research Department, Sheffield Teaching Hospitals NHS Foundation Trust, 
      Sheffield, UK.
FAU - Tracey, Irene
AU  - Tracey I
AD  - FMRIB, Oxford University, Oxford, UK.
FAU - Tesfaye, Solomon
AU  - Tesfaye S
AD  - Diabetes Research Department, Sheffield Teaching Hospitals NHS Foundation Trust, 
      Sheffield, UK.
LA  - eng
PT  - Journal Article
DEP - 20190107
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/01/09 06:00
MHDA- 2019/01/09 06:00
CRDT- 2019/01/09 06:00
PHST- 2018/06/13 00:00 [received]
PHST- 2018/12/13 00:00 [accepted]
PHST- 2019/01/09 06:00 [entrez]
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2019/01/09 06:00 [medline]
AID - db18-0509 [pii]
AID - 10.2337/db18-0509 [doi]
PST - aheadofprint
SO  - Diabetes. 2019 Jan 7. pii: db18-0509. doi: 10.2337/db18-0509.

PMID- 30617143
OWN - NLM
STAT- Publisher
LR  - 20190108
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Jan 7
TI  - Should Viscous Fiber Supplements Be Considered in Diabetes Control? Results From 
      a Systematic Review and Meta-analysis of Randomized Controlled Trials.
LID - dc181126 [pii]
LID - 10.2337/dc18-1126 [doi]
AB  - OBJECTIVE: Evidence from randomized controlled trials (RCTs) suggests that
      viscous dietary fiber may offer beneficial effects on glycemic control and, thus,
      an improved cardiovascular disease risk profile. Our purpose was to conduct a
      systematic review and meta-analysis of RCTs to synthesize the therapeutic effect 
      of viscous fiber supplementation on glycemic control in type 2 diabetes. RESEARCH
      DESIGN AND METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled 
      Trials were searched through 15 June 2018. We included RCTs >/=3 weeks in
      duration that assessed the effects of viscous fiber on markers of glycemic
      control in type 2 diabetes. Two independent reviewers extracted data. Data were
      pooled using the generic inverse variance method and expressed as mean
      differences (MD) with 95% CIs. Heterogeneity was assessed (Cochran Q statistic)
      and quantified (I (2) statistic). The Grading of Recommendations Assessment,
      Development, and Evaluation (GRADE) approach was used to evaluate the overall
      certainty of the evidence. RESULTS: We identified 28 eligible trial comparisons
      (n = 1,394). Viscous fiber at a median dose of approximately 13.1 g/day
      significantly reduced HbA1c (MD -0.58% [95% CI -0.88, -0.28]; P = 0.0002),
      fasting blood glucose (MD -0.82 mmol/L [95% CI -1.32, -0.31]; P = 0.001), and
      HOMA-insulin resistance (IR) (MD -1.89 [95% CI -3.45, -0.33]; P = 0.02) compared 
      with control and in addition to standard of care. The certainty of evidence was
      graded moderate for HbA1c, fasting glucose, fasting insulin, and HOMA-IR and low 
      for fructosamine. CONCLUSIONS: Viscous fiber supplements improve conventional
      markers of glycemic control beyond usual care and should be considered in the
      management of type 2 diabetes.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Jovanovski, Elena
AU  - Jovanovski E
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
AD  - Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
      Toronto, Canada.
FAU - Khayyat, Rana
AU  - Khayyat R
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
AD  - Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
      Toronto, Canada.
FAU - Zurbau, Andreea
AU  - Zurbau A
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
AD  - Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
      Toronto, Canada.
FAU - Komishon, Allison
AU  - Komishon A
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
FAU - Mazhar, Nourah
AU  - Mazhar N
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
AD  - Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
      Toronto, Canada.
FAU - Sievenpiper, John L
AU  - Sievenpiper JL
AUID- ORCID: http://orcid.org/0000-0002-3270-5772
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
AD  - Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
      Toronto, Canada.
AD  - Toronto 3D Knowledge Synthesis and Clinical Trials Unit, St. Michael's Hospital, 
      Toronto, Canada.
AD  - Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto,
      Canada.
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
FAU - Blanco Mejia, Sonia
AU  - Blanco Mejia S
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
AD  - Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
      Toronto, Canada.
AD  - Toronto 3D Knowledge Synthesis and Clinical Trials Unit, St. Michael's Hospital, 
      Toronto, Canada.
FAU - Ho, Hoang Vi Thanh
AU  - Ho HVT
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
FAU - Li, Dandan
AU  - Li D
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
AD  - Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
      Toronto, Canada.
FAU - Jenkins, Alexandra L
AU  - Jenkins AL
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada.
FAU - Duvnjak, Lea
AU  - Duvnjak L
AD  - Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases,
      Merkur University Hospital, University of Zagreb School of Medicine, Zagreb,
      Croatia.
FAU - Vuksan, Vladimir
AU  - Vuksan V
AUID- ORCID: http://orcid.org/0000-0001-8541-4058
AD  - Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,
      Toronto, Canada v.vuksan@utoronto.ca.
AD  - Department of Nutritional Sciences, Faculty of Medicine, University of Toronto,
      Toronto, Canada.
AD  - Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto,
      Canada.
AD  - Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
LA  - eng
PT  - Journal Article
DEP - 20190107
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/01/09 06:00
MHDA- 2019/01/09 06:00
CRDT- 2019/01/09 06:00
PHST- 2018/05/23 00:00 [received]
PHST- 2018/09/19 00:00 [accepted]
PHST- 2019/01/09 06:00 [entrez]
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2019/01/09 06:00 [medline]
AID - dc18-1126 [pii]
AID - 10.2337/dc18-1126 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Jan 7. pii: dc18-1126. doi: 10.2337/dc18-1126.

PMID- 30629195
OWN - NLM
STAT- Publisher
LR  - 20190110
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2019 Jan 9
TI  - Predictors of long-term glycemic remission after 2-week intensive insulin
      treatment in newly diagnosed type 2 diabetes.
LID - 10.1210/jc.2018-01468 [doi]
AB  - Context: Although several studies suggest that improved beta-cell function is a
      key determinant of glycemic remission in type 2 diabetes, other predictors remain
      unclear. Objective: The aim of this clamp-based study was to identify predictors 
      of 2-year glycemic remission after short-term intensive insulin treatment.
      Design: A 2-year follow-up was planned in 124 drug-naive type 2 diabetic patients
      who received continuous subcutaneous insulin infusion (CSII) for 2 weeks.
      Euglycemic-hyperinsulinemic clamps and intravenous glucose tolerance tests were
      performed to assess the insulin sensitivity (glucose infusion rate, GIR) and
      acute insulin response (AIR) pre- and post-CSII. Results: First-phase insulin
      secretion was restored, and the GIR was significantly improved (P<0.0001) after
      the 2-week CSII. Glycemic remission rates were 47.6% and 30.7% after 12 and 24
      months of follow-up, respectively. Cox analysis revealed that a higher post-CSII 
      glucose level (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.15-1.66,
      P=0.0005) and older age at diabetes diagnosis (HR 1.34, 95% CI 1.05-1.72, P=0.02)
      accounted for an increased risk of hyperglycemic relapse. A 1-SD increase in the 
      AIR (HR 0.75, 95% CI 0.57-0.99, P=0.04), GIR (HR 0.67, 95% CI 0.48-0.93, P=0.016)
      post-CSII, and baseline GIR (HR 0.71, 95% CI 0.51-0.99, P=0.047), were inversely 
      associated with this risk. Conclusions: Younger age at diabetes diagnosis, higher
      baseline insulin sensitivity and lower glucose levels after insulin treatment
      significantly favored a 2-year glycemic remission. This long-term remission was
      attributed to both improved insulin sensitivity and enhanced beta-cell function
      after short-term intensive insulin treatment.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Endocrinology, Fuwai Hospital & Chinese Academy of Medical
      Sciences, China.
FAU - Kuang, Jian
AU  - Kuang J
AD  - Department of Endocrinology, Guangdong General Hospital, Guangdong Academy of
      Medical Sciences, China.
FAU - Xu, Mingtong
AU  - Xu M
AD  - Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen
      University, China.
FAU - Gao, Zhengnan
AU  - Gao Z
AD  - Department of Endocrinology, Dalian Municipal Central Hospital, China.
FAU - Li, Qifu
AU  - Li Q
AD  - Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical
      University, China.
FAU - Liu, Shiping
AU  - Liu S
AD  - Department of Endocrinology, the Second Xiangya Hospital of Central South
      University, China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Department of Endocrinology, Peking University Shenzhen Hospital, China.
FAU - Yu, Yerong
AU  - Yu Y
AD  - Department of Endocrinology, West China Hospital, Sichuan University, China.
FAU - Liang, Zhen
AU  - Liang Z
AD  - Department of Endocrinology, Shenzhen Second People's Hospital, China.
FAU - Zhao, Weigang
AU  - Zhao W
AD  - Department of Endocrinology, Peking Union Medical College Hospital, China.
FAU - Yang, Gangyi
AU  - Yang G
AD  - Department of Endocrinology, the Second Affiliated Hospital of Chongqing Medical 
      University, China.
FAU - Li, Ling
AU  - Li L
AD  - Department of Endocrinology, Shengjing Hospital of China Medical University,
      China.
FAU - Wang, Yang
AU  - Wang Y
AD  - Statistics Medical Research & Biometrics Center, National Center for
      Cardiovascular Diseases, Fuwai Hospital, China.
FAU - Li, Guangwei
AU  - Li G
AD  - Department of Endocrinology, Fuwai Hospital & Chinese Academy of Medical
      Sciences, China.
AD  - Department of Endocrinology, China-Japan Friendship Hospital, China.
LA  - eng
PT  - Journal Article
DEP - 20190109
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2019/01/11 06:00
MHDA- 2019/01/11 06:00
CRDT- 2019/01/11 06:00
PHST- 2018/07/05 00:00 [received]
PHST- 2019/01/04 00:00 [accepted]
PHST- 2019/01/11 06:00 [entrez]
PHST- 2019/01/11 06:00 [pubmed]
PHST- 2019/01/11 06:00 [medline]
AID - 5280417 [pii]
AID - 10.1210/jc.2018-01468 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2019 Jan 9. pii: 5280417. doi: 10.1210/jc.2018-01468.

PMID- 30629189
OWN - NLM
STAT- Publisher
LR  - 20190110
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2019 Jan 9
TI  - Youth and long-term dietary calcium intake with risk of impaired glucose
      metabolism and type 2 diabetes in adulthood.
LID - 10.1210/jc.2018-02321 [doi]
AB  - Context: No previous studies have examined the role of youth calcium intake in
      the development of impaired glucose metabolism, particularly those with long-term
      high calcium intake. Objectives: To examine whether youth and long-term (between 
      youth and adulthood) dietary calcium intake is associated with adult impaired
      glucose metabolism and T2D. Design, Setting, and Participants: The Cardiovascular
      Risk in Young Finns Study (YFS) is a 31-year prospective cohort study (n=1134,
      aged 3-18 years at baseline). Exposures: Dietary calcium intake was assessed at
      baseline (1980) and adult follow-ups (2001, 2007 and 2011). Long-term (mean
      between youth and adulthood) dietary calcium intake was calculated. Main outcome 
      measures: Adult impaired fasting glucose (IFG) and T2D. Results: We found no
      evidence for non-linear associations between calcium intake with IFG or T2D among
      females and males (all p for non-linearity>0.05). Higher youth and long-term
      dietary calcium intake was not associated with the risk of IFG or T2D among
      females or males after adjustment for confounders including youth and adult BMI. 
      Conclusions: Youth or long-term dietary calcium intake is not associated with
      adult risk of developing impaired glucose metabolism or T2D.
FAU - Wu, Feitong
AU  - Wu F
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart,
      Australia.
FAU - Juonala, Markus
AU  - Juonala M
AD  - Department of Medicine, University of Turku, Turku, Finland.
AD  - Division of Medicine, Turku University Hospital, Turku, Finland.
AD  - Murdoch Children's Research Institute, Parkville, Victoria, Australia.
FAU - Pahkala, Katja
AU  - Pahkala K
AD  - Research Centre of Applied and Preventive Cardiovascular Medicine; University of 
      Turku, Turku, Finland.
AD  - Paavo Nurmi Centre, Sports & Exercise Medicine Unit, Department of Physical
      Activity and Health, University of Turku, Turku, Finland.
FAU - Buscot, Marie-Jeanne
AU  - Buscot MJ
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart,
      Australia.
FAU - Sabin, Matthew A
AU  - Sabin MA
AD  - Murdoch Children's Research Institute, Royal Children's Hospital, and Department 
      of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.
FAU - Pitkanen, Niina
AU  - Pitkanen N
AD  - Research Centre of Applied and Preventive Cardiovascular Medicine; University of 
      Turku, Turku, Finland.
FAU - Ronnemaa, Tapani
AU  - Ronnemaa T
AD  - Department of Medicine, University of Turku, Turku, Finland.
FAU - Jula, Antti
AU  - Jula A
AD  - National Institute for Health and Welfare, Turku, Finland.
FAU - Lehtimaki, Terho
AU  - Lehtimaki T
AD  - Department of Clinical Chemistry, Fimlab Laboratories and Faculty of Medicine and
      Health Technology, Finnish Cardiovascular Research Center - Tampere, Tampere
      University, Tampere, Finland.
FAU - Hutri-Kahonen, Nina
AU  - Hutri-Kahonen N
AD  - Department of Pediatrics, University of Tampere and Tampere University Hospital, 
      Tampere, Finland.
FAU - Kahonen, Mika
AU  - Kahonen M
AD  - Department of Clinical Physiology, Tampere University Hospital and University of 
      Tampere, Tampere, Finland.
FAU - Laitinen, Tomi
AU  - Laitinen T
AD  - Department of Clinical Physiology and Nuclear Medicine, Kuopio University
      Hospital and University of Eastern Finland, Kuopio, Finland.
FAU - Viikari, Jorma S A
AU  - Viikari JSA
AD  - Department of Medicine, University of Turku, Turku, Finland.
FAU - Raitakari, Olli T
AU  - Raitakari OT
AD  - Research Centre of Applied and Preventive Cardiovascular Medicine; University of 
      Turku, Turku, Finland.
AD  - Department of Clinical Physiology and Nuclear Medicine, Turku University
      Hospital, Turku, Finland.
FAU - Magnussen, Costan G
AU  - Magnussen CG
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart,
      Australia.
AD  - Research Centre of Applied and Preventive Cardiovascular Medicine; University of 
      Turku, Turku, Finland.
LA  - eng
PT  - Journal Article
DEP - 20190109
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2019/01/11 06:00
MHDA- 2019/01/11 06:00
CRDT- 2019/01/11 06:00
PHST- 2018/10/28 00:00 [received]
PHST- 2019/01/03 00:00 [accepted]
PHST- 2019/01/11 06:00 [entrez]
PHST- 2019/01/11 06:00 [pubmed]
PHST- 2019/01/11 06:00 [medline]
AID - 5280418 [pii]
AID - 10.1210/jc.2018-02321 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2019 Jan 9. pii: 5280418. doi: 10.1210/jc.2018-02321.

PMID- 30608562
OWN - NLM
STAT- Publisher
LR  - 20190104
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2019 Jan 3
TI  - Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults with
      Incident Type 2 Diabetes.
LID - 10.1210/jc.2018-01402 [doi]
AB  - Context: HbA1C is an important predictor of severe hypoglycemia. Objective: To
      determine the association of proximal HbA1C level with first hypoglycemia
      requiring hospitalization (HH) in adults with incident type 2 diabetes (T2D).
      Design, Setting, and Participants: A nested case-control study was designed using
      linked data from the Clinical Practice Research Datalink and Hospital Episode
      Statistics in England in 1997-2014. The first hypoglycemia as primary diagnosis
      for hospitalization after T2D diagnosis was identified. Proximal HbA1C was
      measured within 90 days prior to the first HH. Main Outcome Measure: Odds ratio
      (OR) for developing HH. Results: The association of proximal HbA1C level with
      first HH was similar between HbA1C of 6.0% (OR 1.54; 95% CI 1.12-2.11) and 9.0%
      (1.48 [1.01-2.17]), compared to the reference HbA1C level of 7.0%. For proximal
      HbA1C level of 4.0-6.5%, every additional 0.5% increase in HbA1C was associated
      with lower first HH risk with OR (95% CI) ranging between 0.37 (0.20-0.67) and
      0.86 (0.76-0.98). For proximal HbA1C level of 8.0-11.5%, every additional 0.5%
      increase in HbA1C was associated with higher first HH risk with OR (95% CI)
      ranging between 1.16 (1.04-1.29) and 1.34 (1.18-1.52). The U-shaped association
      between proximal HbA1C level and first HH did not exist among current
      sulfonylureas users but persisted among current insulin users
      (Pinteraction=0.002). Among current non-insulin non-sulfonylureas users who had
      first HH, 78% took insulin or sulfonylureas prior to HH. Conclusions: Having
      either poor or near-normal HbA1C was associated with higher risk of first HH in
      T2D within three months.
FAU - Zhong, Victor W
AU  - Zhong VW
AD  - From the Department of Nutrition, Gillings School of Global Public Health,
      University of North Carolina, Chapel Hill, NC, USA.
AD  - Department of Preventive Medicine, Northwestern University Feinberg School of
      Medicine, Chicago, Illinois, USA.
FAU - Juhaeri, Juhaeri
AU  - Juhaeri J
AD  - Global Pharmacovigilance and Epidemiology, Sanofi, Bridgewater, NJ, USA.
FAU - Cole, Stephen R
AU  - Cole SR
AD  - Department of Epidemiology, Gillings School of Global Public Health, University
      of North Carolina, Chapel Hill, NC, USA.
FAU - Shay, Christina M
AU  - Shay CM
AD  - Center for Health Metrics and Evaluation, the American Heart Association, Dallas,
      TX, USA.
FAU - Gordon-Larsen, Penny
AU  - Gordon-Larsen P
AD  - From the Department of Nutrition, Gillings School of Global Public Health,
      University of North Carolina, Chapel Hill, NC, USA.
AD  - Carolina Population Center, University of North Carolina at Chapel Hill, Chapel
      Hill, NC, USA.
AD  - Department of Medicine, School of Medicine, University of North Carolina, Chapel 
      Hill, NC, USA.
FAU - Kontopantelis, Evangelos
AU  - Kontopantelis E
AD  - Farr Institute for Health Informatics Research, University of Manchester,
      Manchester, UK.
FAU - Mayer-Davis, Elizabeth J
AU  - Mayer-Davis EJ
AD  - From the Department of Nutrition, Gillings School of Global Public Health,
      University of North Carolina, Chapel Hill, NC, USA.
AD  - Department of Medicine, School of Medicine, University of North Carolina, Chapel 
      Hill, NC, USA.
LA  - eng
PT  - Journal Article
DEP - 20190103
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2019/01/05 06:00
MHDA- 2019/01/05 06:00
CRDT- 2019/01/05 06:00
PHST- 2018/06/27 00:00 [received]
PHST- 2018/12/28 00:00 [accepted]
PHST- 2019/01/05 06:00 [entrez]
PHST- 2019/01/05 06:00 [pubmed]
PHST- 2019/01/05 06:00 [medline]
AID - 5270382 [pii]
AID - 10.1210/jc.2018-01402 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2019 Jan 3. pii: 5270382. doi: 10.1210/jc.2018-01402.

PMID- 30424891
OWN - NLM
STAT- MEDLINE
DCOM- 20190109
LR  - 20190109
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 393
IP  - 10166
DP  - 2019 Jan 5
TI  - Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
PG  - 3-5
LID - S0140-6736(18)32824-1 [pii]
LID - 10.1016/S0140-6736(18)32824-1 [doi]
FAU - Verma, Subodh
AU  - Verma S
AD  - Division of Cardiac Surgery, St Michael's Hospital, University of Toronto,
      Toronto M5B 1W8, ON, Canada; Applied Health Research Centre, Li Ka Shing
      Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada. Electronic
      address: vermasu@smh.ca.
FAU - Juni, Peter
AU  - Juni P
AD  - Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's
      Hospital, Toronto, ON, Canada.
FAU - Mazer, C David
AU  - Mazer CD
AD  - Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's
      Hospital, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Comment
DEP - 20181110
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - AIM
SB  - IM
CON - Lancet. 2019 Jan 5;393(10166):31-39. PMID: 30424892
MH  - Canagliflozin
MH  - *Diabetes Mellitus, Type 2
MH  - Humans
MH  - Hypoglycemic Agents
MH  - Secondary Prevention
MH  - *Sodium-Glucose Transporter 2 Inhibitors
EDAT- 2018/11/15 06:00
MHDA- 2019/01/10 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/10/18 00:00 [received]
PHST- 2018/10/29 00:00 [accepted]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2019/01/10 06:00 [medline]
PHST- 2018/11/15 06:00 [entrez]
AID - S0140-6736(18)32824-1 [pii]
AID - 10.1016/S0140-6736(18)32824-1 [doi]
PST - ppublish
SO  - Lancet. 2019 Jan 5;393(10166):3-5. doi: 10.1016/S0140-6736(18)32824-1. Epub 2018 
      Nov 10.